OmniAb to report Q2 2026 results on August 6
OmniAb will report financial results for the three and six months ended June 30, 2026, after market close on August 6. A conference call will follow at 4:30 p.m. ET to discuss the results and business updates.
*this image is generated using AI for illustrative purposes only.
OmniAb will report financial results for the three and six months ended June 30, 2026, after the close of U.S. financial markets on Thursday, August 6, 2026. The company will hold a conference call the same day to discuss the results and provide business updates.
Conference Call Details
The call is scheduled to begin at 4:30 p.m. Eastern time. Investors can access the call via phone or webcast. The event will include a live and replay webcast with slides available online.
| Detail | Information |
|---|---|
| Date | Thursday, August 6, 2026 |
| Time | 4:30 p.m. Eastern time (1:30 p.m. Pacific time) |
| U.S. Phone | (833) 461-5787 |
| International Phone | (585) 542-9983 |
| Conference ID | 545137839 |
| Webcast | Available on the company's website |
OmniAb licenses discovery research technology to pharmaceutical and biotech companies and academic institutions. Its platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for drug development. The company's business model includes upfront fees, service revenue, milestones, and royalties on commercial sales.
What key performance indicators should investors focus on during the conference call to gauge OmniAb's growth trajectory?
How might the upcoming financial results influence OmniAb's partnerships with pharmaceutical and biotech companies?
What potential milestones or royalties could significantly impact OmniAb's revenue in the second half of 2026?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
